Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free BIOG Stock Alerts

The Biotech Growth Trust (BIOG) Competitors

The Biotech Growth Trust logo
GBX 1,262 +22.00 (+1.77%)
As of 12:00 PM Eastern
Compare

BIOG vs. GROW, TRY, JPE, SOI, and BBGI

Should you buy The Biotech Growth Trust stock or one of its competitors? MarketBeat compares The Biotech Growth Trust with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with The Biotech Growth Trust include Molten Ventures (GROW), TR Property Investment Trust (TRY), JPMorgan Elect plc ­- Managed Growth (JPE), Schroder Oriental Income (SOI), and BBGI Global Infrastructure (BBGI). These companies are all part of the "asset management" industry.

How does The Biotech Growth Trust compare to Molten Ventures?

The Biotech Growth Trust (LON:BIOG) and Molten Ventures (LON:GROW) are both small-cap financial services companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Molten Ventures had 4 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 5 mentions for Molten Ventures and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.42 beat Molten Ventures' score of 1.15 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
The Biotech Growth Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Molten Ventures
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

10.5% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 41.3% of Molten Ventures shares are owned by institutional investors. 2.9% of The Biotech Growth Trust shares are owned by insiders. Comparatively, 1.6% of Molten Ventures shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

The Biotech Growth Trust has a beta of 0.59646654, indicating that its share price is 40% less volatile than the broader market. Comparatively, Molten Ventures has a beta of 1.9414055, indicating that its share price is 94% more volatile than the broader market.

Molten Ventures has a consensus target price of GBX 599.67, suggesting a potential downside of 3.59%. Given Molten Ventures' stronger consensus rating and higher possible upside, analysts clearly believe Molten Ventures is more favorable than The Biotech Growth Trust.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
The Biotech Growth Trust
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Molten Ventures
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Molten Ventures has a net margin of 193.06% compared to The Biotech Growth Trust's net margin of 96.47%. The Biotech Growth Trust's return on equity of 48.26% beat Molten Ventures' return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
Molten Ventures 193.06%8.81%-3.46%

The Biotech Growth Trust has higher earnings, but lower revenue than Molten Ventures. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Molten Ventures, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26
Molten Ventures£125.60M8.53-£33.58M£61.6010.10

Summary

Molten Ventures beats The Biotech Growth Trust on 10 of the 16 factors compared between the two stocks.

How does The Biotech Growth Trust compare to TR Property Investment Trust?

The Biotech Growth Trust (LON:BIOG) and TR Property Investment Trust (LON:TRY) are both small-cap financial services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

10.5% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 12.8% of TR Property Investment Trust shares are owned by institutional investors. 2.9% of The Biotech Growth Trust shares are owned by insiders. Comparatively, 0.2% of TR Property Investment Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, TR Property Investment Trust had 6 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 7 mentions for TR Property Investment Trust and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.42 beat TR Property Investment Trust's score of 1.13 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
The Biotech Growth Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TR Property Investment Trust
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

TR Property Investment Trust has lower revenue, but higher earnings than The Biotech Growth Trust. TR Property Investment Trust is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26
TR Property Investment Trust-£27.26M-35.74£284.71M-£11.35N/A

The Biotech Growth Trust has a net margin of 96.47% compared to TR Property Investment Trust's net margin of 79.93%. The Biotech Growth Trust's return on equity of 48.26% beat TR Property Investment Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
TR Property Investment Trust 79.93%6.52%-24.58%

The Biotech Growth Trust has a beta of 0.59646654, meaning that its stock price is 40% less volatile than the broader market. Comparatively, TR Property Investment Trust has a beta of 1.4909836, meaning that its stock price is 49% more volatile than the broader market.

Summary

The Biotech Growth Trust beats TR Property Investment Trust on 9 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to JPMorgan Elect plc ­- Managed Growth?

JPMorgan Elect plc ­- Managed Growth (LON:JPE) and The Biotech Growth Trust (LON:BIOG) are both small-cap asset management industry companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

The Biotech Growth Trust has a net margin of 96.47% compared to JPMorgan Elect plc ­- Managed Growth's net margin of 0.00%. The Biotech Growth Trust's return on equity of 48.26% beat JPMorgan Elect plc ­- Managed Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
JPMorgan Elect plc ­- Managed GrowthN/A N/A N/A
The Biotech Growth Trust 96.47%48.26%12.39%

In the previous week, The Biotech Growth Trust had 1 more articles in the media than JPMorgan Elect plc ­- Managed Growth. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for JPMorgan Elect plc ­- Managed Growth. The Biotech Growth Trust's average media sentiment score of 1.42 beat JPMorgan Elect plc ­- Managed Growth's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
JPMorgan Elect plc ­- Managed Growth Neutral
The Biotech Growth Trust Positive

10.5% of The Biotech Growth Trust shares are owned by institutional investors. 2.9% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

The Biotech Growth Trust has lower revenue, but higher earnings than JPMorgan Elect plc ­- Managed Growth. JPMorgan Elect plc ­- Managed Growth is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JPMorgan Elect plc ­- Managed Growth£104.78M0.00N/A£0.75N/A
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26

Summary

The Biotech Growth Trust beats JPMorgan Elect plc ­- Managed Growth on 8 of the 10 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Schroder Oriental Income?

The Biotech Growth Trust (LON:BIOG) and Schroder Oriental Income (LON:SOI) are both small-cap asset management industry companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

10.5% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 9.7% of Schroder Oriental Income shares are owned by institutional investors. 2.9% of The Biotech Growth Trust shares are owned by insiders. Comparatively, 0.1% of Schroder Oriental Income shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than Schroder Oriental Income. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for Schroder Oriental Income. The Biotech Growth Trust's average media sentiment score of 1.42 beat Schroder Oriental Income's score of 0.20 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company Overall Sentiment
The Biotech Growth Trust Positive
Schroder Oriental Income Neutral

The Biotech Growth Trust has a beta of 0.59646654, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Schroder Oriental Income has a beta of 0.645, suggesting that its share price is 36% less volatile than the broader market.

The Biotech Growth Trust has a net margin of 96.47% compared to Schroder Oriental Income's net margin of 94.62%. The Biotech Growth Trust's return on equity of 48.26% beat Schroder Oriental Income's return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
Schroder Oriental Income 94.62%39.20%-2.12%

Schroder Oriental Income has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Schroder Oriental Income, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26
Schroder Oriental Income£334.18M2.87£106.18M£144.692.97

Summary

The Biotech Growth Trust beats Schroder Oriental Income on 8 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to BBGI Global Infrastructure?

BBGI Global Infrastructure (LON:BBGI) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

58.9% of BBGI Global Infrastructure shares are owned by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are owned by institutional investors. 0.5% of BBGI Global Infrastructure shares are owned by insiders. Comparatively, 2.9% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BBGI Global Infrastructure has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59646654, suggesting that its share price is 40% less volatile than the broader market.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than BBGI Global Infrastructure. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for BBGI Global Infrastructure. The Biotech Growth Trust's average media sentiment score of 1.42 beat BBGI Global Infrastructure's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
BBGI Global Infrastructure Neutral
The Biotech Growth Trust Positive

The Biotech Growth Trust has a net margin of 96.47% compared to BBGI Global Infrastructure's net margin of 61.84%. The Biotech Growth Trust's return on equity of 48.26% beat BBGI Global Infrastructure's return on equity.

Company Net Margins Return on Equity Return on Assets
BBGI Global Infrastructure61.84% 2.52% 3.32%
The Biotech Growth Trust 96.47%48.26%12.39%

The Biotech Growth Trust has lower revenue, but higher earnings than BBGI Global Infrastructure. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than BBGI Global Infrastructure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BBGI Global Infrastructure£67.98M14.48£54.89M£7.7217.93
The Biotech Growth Trust-£17.73M-13.81£83.83M£558.002.26

Summary

The Biotech Growth Trust beats BBGI Global Infrastructure on 9 of the 13 factors compared between the two stocks.

Get The Biotech Growth Trust News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIOG vs. The Competition

Export
MetricThe Biotech Growth TrustAsset Management IndustryFinancial SectorLON Exchange
Market Cap£244.83M£2.42B£5.74B£2.73B
Dividend YieldN/A6.03%5.29%6.13%
P/E Ratio2.2625.7116.33366.48
Price / Sales-13.812,038.131,092.7886,600.07
Price / Cash87.7460.3389.1227.87
Price / Book1.171.366.517.62
Net Income£83.83M£265.36M£1.13B£5.89B
7 Day Performance0.16%-0.80%0.05%-1.35%
1 Month Performance-6.52%-0.69%0.73%0.48%
1 Year Performance63.05%9.39%18.55%69.72%

The Biotech Growth Trust Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIOG
The Biotech Growth Trust
N/AGBX 1,262
+1.8%		N/A+62.3%£244.83M-£17.73M2.26N/A
GROW
Molten Ventures
1.4778 of 5 stars		GBX 589
+1.5%		GBX 599.67
+1.8%		+96.5%£1.01B£125.60M9.5620
TRY
TR Property Investment Trust
N/AGBX 317
-0.2%		N/A-8.2%£1.01B-£27.26MN/A26
JPE
JPMorgan Elect plc ­- Managed Growth
N/AN/AN/AN/A£1.00B£104.78M1,250.00N/A
SOI
Schroder Oriental Income
N/AGBX 440
flat		N/A+50.7%£986.61M£97.72M10.86180

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BIOG) was last updated on 6/11/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
"Golden Dawn": the code name that should be on every investor's radar
Trump's team has officially code-named America's new AI initiative 'Golden Dawn' - a government project involv...
InvestorPlace | Sponsoredtc pixel